Please login to the form below

Not currently logged in
Email:
Password:

ciprofloxacin

This page shows the latest ciprofloxacin news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

Aradigm has been unable to convince an FDA advisory committee that that its inhaled version of ciprofloxacin should be approved for chronic infections in patients with a serious lung disease.

Latest news

  • Bayer drug-device combo for pneumonia flunks phase III test Bayer drug-device combo for pneumonia flunks phase III test

    The two companies have also collaborated on Cipro Inhale, a drug-device combination based on ciprofloxacin that was rejected by a US FDA advisory committee last week as a treatment to

  • Untreatable gonorrhoea on the march worldwide, says WHO Untreatable gonorrhoea on the march worldwide, says WHO

    WHO surveillance reveals a 97% resistance rate to common first-line agent ciprofloxacin, 81% to azithromycin and 66% resistance to the current last-resort treatment - the extended-spectrum cephalosporins oral cefixime

  • Pfizer recalls contaminated IV drugs

    Pfizer has recalled batches of the antibiotics metronidazole and ciprofloxacin and the anti-emetic ondansetron after the manufacturer, India-based Claris Laboratories, discovered contamination in the plastic intravenous (IV) bags containing

  • Bayer sues Canadian hospital for Cipro patent infringement

    German pharmaceutical company Bayer has sued a hospital in Ontario, Canada, for patent infringement, accusing it of copying the antibiotic Cipro (ciprofloxacin) by diluting a generic version. ... Ciprofloxacin is prescribed to treat urinary-tract and

  • Depomed and Watson sign co-promotion deal

    Extended release versions of ciprofloxacin are also sold by Germany-based Bayer and Indian pharmaceutical company Ranbaxy. ... The fluoroquinolone market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65 per cent (USD 3.3bn

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics